About NewAmsterdam Pharma Company N.V.
https://www.newamsterdampharma.comNewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases.
CEO
Michael Harvey Davidson Facp.
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public February 10, 2021
Full time employees 68
Ratings Snapshot
Rating : C+
Discounted Cash Flow 3
Return On Equity 1
Return On Assets 1
Debt To Equity 4
Price To Earnings 1
Price To Book 3
Overall Score 2
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Market Cap $2.25 B
52w High $29.99
52w Low $5.45
P/E 0
Volume 261
Outstanding Shares 113.32M
About NewAmsterdam Pharma Company N.V.
https://www.newamsterdampharma.comNewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $348K ▼ | $55.49M ▲ | $-72M ▼ | -20.69K% ▼ | $-0.61 ▼ | $-71.94M ▼ |
| Q2-2025 | $19.14M ▲ | $54.78M ▼ | $-17.36M ▲ | -90.7% ▲ | $-0.15 ▲ | $-35.59M ▲ |
| Q1-2025 | $2.98M ▼ | $71.9M ▲ | $-39.53M ▲ | -1.33K% ▼ | $-0.34 ▲ | $-68.87M ▲ |
| Q4-2024 | $12.77M ▼ | $56M ▲ | $-92.18M ▼ | -721.71% ▼ | $-0.98 ▼ | $-111.69M ▼ |
| Q3-2024 | $29.11M | $54.11M | $-16.65M | -57.18% | $-0.18 | $-23.84M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $702.95M ▼ | $786.43M ▼ | $58.36M ▲ | $728.07M ▼ |
| Q2-2025 | $739.16M ▼ | $815.11M ▼ | $36.62M ▼ | $778.5M ▲ |
| Q1-2025 | $808.48M ▼ | $818.41M ▼ | $41.05M ▼ | $777.36M ▲ |
| Q4-2024 | $834.19M ▲ | $864.62M ▲ | $107.12M ▲ | $757.5M ▲ |
| Q3-2024 | $422.73M | $439.19M | $60.33M | $378.86M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $39.53M ▲ | $-32.77M ▲ | $2.51M ▲ | $5.89M ▲ | $-24.15M ▲ | $-32.81M ▲ |
| Q2-2025 | $0 ▲ | $-37.67M ▼ | $-159.14M ▼ | $3.42M ▼ | $-184.56M ▼ | $-37.76M ▼ |
| Q1-2025 | $-39.53M ▲ | $-36.47M ▲ | $2.85M ▲ | $6.52M ▼ | $-23.32M ▼ | $-36.48M ▲ |
| Q4-2024 | $-92.18M ▼ | $-37.48M ▼ | $-62.18M ▼ | $456.61M ▲ | $349.01M ▲ | $-37.48M ▼ |
| Q3-2024 | $-16.65M | $-12.5M | $-75K | $58K | $-7.98M | $-12.58M |
CEO
Michael Harvey Davidson Facp.
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public February 10, 2021
Full time employees 68
Ratings Snapshot
Rating : C+
Discounted Cash Flow 3
Return On Equity 1
Return On Assets 1
Debt To Equity 4
Price To Earnings 1
Price To Book 3
Overall Score 2
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0